Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
[Blood and Lymphatic Cancer: Targets and Therapy] Although this retrospective analysis determined that ibrutinib was not associated with higher mortality in older patients with CLL, it did find greater intolerance with an increased number of early deaths in elderly patients treated with ibrutinib.
Clinical trial results indicate that adolescent patients with acute lymphoblastic leukemia have poorer outcomes than younger patients do.
The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.